Amphastar Pharmaceuticals, Inc. (AMPH) FY2026 YTD Q2 P&L / Income Statement

Amphastar Pharmaceuticals, Inc. (AMPH) FY2026 YTD Q2 P&L / Income Statement

Income statement for 2026-01-01 through 2026-06-30. View: Segments by Subsegments. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Revenues

355,074,000 US dollars

Cost of revenues

191,282,000 US dollars

Gross profit

163,792,000 US dollars

Total operating expenses

110,433,000 US dollars

Income from operations

53,359,000 US dollars

Total non-operating income (expenses), net

negative 4,763,000 US dollars

Income before income taxes

48,596,000 US dollars

Income tax provision

11,828,000 US dollars

Net income

36,768,000 US dollars

Finished Pharmaceutical Products Segment - BAQSIMI

77,937,000 US dollars

Finished Pharmaceutical Products Segment - Epinephrine

35,067,000 US dollars

Finished Pharmaceutical Products Segment - Glucagon

21,075,000 US dollars

Finished Pharmaceutical Products Segment - Ipratropium Bromide

8,411,000 US dollars

Finished Pharmaceutical Products Segment - Lidocaine

28,499,000 US dollars

Finished Pharmaceutical Products Segment - Other Products

133,318,000 US dollars

Finished Pharmaceutical Products Segment - Primatene MIST

50,767,000 US dollars

Research and development

48,901,000 US dollars

General and administrative

36,270,000 US dollars

Selling, distribution, and marketing

25,262,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.